This inventor holds 9 USPTO granted patents and 3 published patent applications and 3 EPO patents. Top assignees: Furuno Electric Company Limited, Sumitomo Pharma Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd.. Active years: 2012-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Nishinomiya, JP (2012 - 2017)
- Osaka, JP (2020 - 2024)
Company Filing History:

Years Active: 2012-2026
Title: Satoshi Adachi: Innovator in Medicinal Chemistry
Introduction
Satoshi Adachi is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds for treating neuropsychiatric diseases. With a total of 9 patents to his name, Adachi's work has garnered attention in both academic and industrial circles.
Latest Patents
Among his latest patents is a formulation involving substituted pyrazoles that exhibit serotonin 5-HT receptor activity. This invention relates to a medicament designed for treating neuropsychiatric diseases, comprising a compound of Formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient. Another notable patent is for bicyclic pyridine derivatives, which provides innovative compounds represented by a specific formula.
Career Highlights
Satoshi Adachi has worked with notable companies such as Furuno Electric Company Limited and Sumitomo Pharma Co., Ltd. His experience in these organizations has allowed him to apply his expertise in developing groundbreaking medicinal compounds.
Collaborations
Adachi has collaborated with esteemed colleagues, including Hidefumi Yoshinaga and Yohei Ikuma. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.
Conclusion
Satoshi Adachi's contributions to medicinal chemistry and his innovative patents highlight his role as a key figure in the field. His work continues to influence the development of new treatments for neuropsychiatric conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile